ReviewExpert opinion on investigational drugs2010

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.

John T IsaacsPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.